livemint.com
95%
284
AstraZeneca covid-19 vaccine shows 76% efficacy in updated data from US trial
Also Read | Lessons from India’s tryst with lockdownAstraZeneca had on Monday announced its first set of interim results from the phase 3 trial in the US, Chile and Peru, showing that its vaccine, which it co-developed with the University of Oxford, had an efficacy of 79%.However, a US government agency, National Institute of Allergy and Infectious Diseases (NIAID), a day later said that the trial’s DSMB had notified that AstraZeneca may have used outdated information from the US trial, which may have provided an incomplete view of efficacy data.After NIAID’s statement on Tuesday, AstraZeneca said that Monday’s results were based on a pre-specified interim analysis with a data cut-off of 17 February and that it will immediately engage with